Abstract
Objective: To determine the effectiveness of combination therapy with Sofosbuvir and Daclatasvir in HCV infected patients
Material and Methods: This quasi experimental study spanning over six months from January 2019 till June 2019 was conducted in three tertiary care teaching hospitals of Khyber Pakhtunkhwa. A total of 255 RT-PCR confirmed genotype HCV
infected patients were included. Combination therapy including standard dose Sofosbuvir (400mg) and Daclatasvir (60mg)
regimen for 12 weeks was administered after recording baseline data. The SVR12 (sustained virologic response after 12
weeks) in these patients was observed by repeating the RT-PCR for HCV at 12 weeks after the completion of treatment.
Results: This study included 108(42.35 %) male and 147 (57.64 %) female with male to female ratio of 1: 1.36 and Mean age
42.23 ± 11.9 years. Among them 200 (78.4%) were treatment naïve and 55 (21.6%) were treatment experienced. A total
of 249 patients (97.6%) achieved SVR12 responders and 06 patients (2.4%) failed to achieve SVR12 non-responders. This
response to DAA treatment for HCV was clinically and statistically significant.
Conclusion: The standard three-month DAA therapy with Sofosbuvir and Daclatasvir for the treatment of HCV has better
SVR12 when compared with conventional treatment.
Zia Uddin, Shams Suleman, Shahzeb, Inayat Ullah, Zahid Fida, Shahab Uddin Zia. (2020) EFFECTIVENESS OF COMBINATION THERAPY WITH SOFOSBUVIR AND DACLATASVIR IN HCV INFECTED PATIENTS, Journal of Medical Sciences, Volume 28, Issue 3.
-
Views
810 -
Downloads
47
